Jupiter Neurosciences Launches Nugevia™ Longevity Supplement Line to Drive Revenue and Address Growing Market

Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company, has launched Nugevia™, its direct-to-consumer longevity product line, marking a significant milestone in its dual business strategy. The launch represents a strategic move to generate revenue and cash flow through consumer products while continuing development of prescription drugs for central nervous system disorders and rare diseases. This approach reduces the company's dependency on the lengthy clinical process, which can take years from development to market.

The scientifically backed longevity market, valued at $65 billion in 2023 and projected to reach $314 billion by 2030, presents substantial opportunity. Jupiter Neurosciences estimates the combined addressable market for mind, beauty, and energy products at $8 trillion globally. Nugevia products are powered by JOTROL™, the company's patent-protected resveratrol formulation with over eight years of pharmaceutical development. Resveratrol is known for its antioxidant and anti-inflammatory effects, activation of PARP-1 protein for DNA repair, cardiovascular benefits, cognitive enhancement, and antibacterial properties against food-borne pathogens.

The initial three formulations target key areas of consumer interest: mitochondrial support, mental clarity, and beauty from within. Nugevia GLO is designed to support skin health through cellular defense, collagen integrity, and hydration. Nugevia PWR focuses on mitochondrial health to support cellular energy, endurance, and recovery. Nugevia MND aims to protect and enhance cognitive function and overall brain health. The company emphasizes that these products feature precision-engineered "intelligent stacking" of synergistic compounds rather than single-ingredient formulations, enhancing cellular resilience, supporting blood-brain barrier delivery, and promoting system-wide optimization.

Christer Rosen, Chairman and CEO of Jupiter Neurosciences, stated that the launch represents the natural progression of translating scientific research into real-world impact. The company has appointed professional golfer Annika Sörenstam as its first brand ambassador to build awareness. Sörenstam, with over 95 international tournament wins including 72 LPGA titles, will advocate for the brand's mission of supporting healthy aging and optimal function. The products will be available directly to consumers through a DTC model beginning this fall, providing immediate revenue generation while the company continues its clinical drug development pipeline.